AASLD: American Association for the Study of Liver Diseases
Home | Contact Us
About Us | News | JoinPatients | AASLD Foundation | Special Interest Groups | Committees
 

Drug-Induced Liver Injury 2009 Program 
|

Hepatotoxicity Special Interest Group
Note: this meeting was held April 8-9, 2009

Recent Research Advances in Drug-Induced Liver Injury

A national/international discussion of recent new findings in the field of drug-induced liver injury (DILI), work in progress, and work that needs to be done.

The program was co-sponsored by the Food and Drug Administration/Center for Drug Evaluation and Research (FDA/CDER), the Pharmaceutical Research and Manufacturers of America (PhRMA), and AASLD.

 Archived Meetings

2013
2012
2011
2010

2008-1999 (available on FDA website)

 

Program with Presenter Slides
(Note: Click on a Speaker's Name to View His/Her Presentation Slides.)

Wednesday, April 8, 2009
8:00am

Introductions and Opening Statements
Welcome
Lana Pauls and John Senior (Co-Chairs)
Food and Drug Administration / Center for Drug Evaluation and Research

Janet Woodcock - FDA / CDER
Alan Goldhammer - PhRMA
Neil Kaplowitz - AASLD

 

Session I -  Moderator: Roger Ulrich - Calistoga Pharmaceuticals

Session IA: Genetic Susceptibility to DILI or Liver Disease
8:15am

Systems Biology Approach to Ximelagatran Injury
Karin Cederbrant
AstraZeneca

8:45am

MHC II Haplotype Marker for Lumiracoxib Injury
Tim Wright
Novartis

9:15am

Powerful HLA Marker of Flucloxicillin Injury Susceptibility
Ann Daly
University of Newcastle

Session IB: Can Animals be Used to Show Idiosyncratic Responses?
10:15am The Mouse as A Model for Susceptibility to DILI
Ivan Rusyn
University of North Carolina
10:45am

Idiosyncrasy in Ordinary Laboratory Animals
John Senior
Food and Drug Administration / Center for Drug Evaluation and Research

11:15am Mouse Models of Halothane-Induced Liver Injury
Cynthia Ju
University of Colorado
Session I Discussion
 
Session II - Moderator: Paul Watkins - University of North Carolina
Session IIA: Findings from DILI Genetic Networks
1:15pm Findings from the SAEC International Network
Matt Nelson
GlaxoSmithKline
2:00pm The Spanish DILI Network
Raúl Andrade
University of Malaga
Session IIB: What Do the Gene Findings Mean for DILI  Mechanisms?
3:45pm Genotype-Phenotype Relationships
Roger Ulrich
Calistoga Pharmaceuticals
4:15pm Implications of Genetic Susceptibility to DILI
David Goldstein
Duke University
4:45pm Mechanisms of Liver Injury in Susceptible People
Neil Kaplowitz
University of South Carolina
Session II Discussion
 
Thursday, April 9, 2009
Session III - Moderator: Leonard Seeff - National Institutes of Health / NIDDK
Session IIIA: Research in Progress A
8:00am Screening Populations for Transaminase Elevations
Heide Stirnadel
GlaxoSmithKline-United Kingdom
8:20am Metabolic Effects in Subjects Taking Acetaminophen
Tom O'Connell
University of North Carolina
8:40am

Update on Acetaminophen Hepatotoxicity
Will Lee
University of Texas Southwestern

9:00am Liver Injury in Patients on Anti-Tuberculosis Therapy
Jussi Saukkonen
Boston University
Session IIIB: Research in Progress B
10:30am Cellular Imaging of Hepatocytes to Predict DILI
Michael Aleo
Pfizer
10:50am

Blood Transcriptomic Findings in Acute Liver Injury
Rick Paules
National Institutes of Environmental Health Sciences

11:10am Human Hepatocyte Cultures for Study of DILI
Sangeeta Bhatia
Massachusetts Institute of Technology
11:30am Update on Liver Transplants for DI-ALF
Arie Regev
Lilly
Session III Discussion
 
Session IV -  Moderator: Lana Pauls - Food and Drug Administration / CDER
Session IV: Research that Needs to be Done
1:30pm Research Opportunities Under the New FDA Guidance
Mark Avigan
Food and Drug Administration / Center for Drug Evaluation and Research
1:55pm Using eDISH-like methods to track possible hepatotoxicity: Case Studies
Jack Ostroff
Pfizer
2:20pm IOM and DILIN Suggestions and Plans
Paul Watkins
University of North Carolina
2:40pm In Silico Simulation of DILI Using the Entelos Platform
Harvey Clewell
The Hamner
Session IV Discussion